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Key points
 Heart failure is characterised by limb and respiratory muscle impairments that limit functional
capacity and quality of life. However, compared with heart failure with reduced ejection fraction
(HFrEF), skeletal muscle alterations induced by heart failure with preserved ejection fraction
(HFpEF) remain poorly explored.
 Here we report that obese-HFpEF inducesmultiple skeletal muscle alterations in the rat hindlimb,
including impaired muscle mechanics related to shortening velocity, fibre atrophy, capillary loss,
and an impaired blood flow response to contractions that implies a perfusive oxygen delivery
limitation.
 We also demonstrate that obese-HFpEF is characterised by diaphragmatic alterations similar to
those caused by denervation – atrophy in Type IIb/IIx (fast/glycolytic) fibres and hypertrophy in
Type I (slow/oxidative) fibres.
 These findings extend current knowledge inHFpEF skeletalmuscle physiology, potentially under-
lying exercise intolerance, which may facilitate future therapeutic approaches.
Abstract Peripheral skeletal muscle and vascular alterations induced by heart failure with pre-
served ejection fraction (HFpEF) remain poorly identified, with limited therapeutic targets. This
study used a cardiometabolic obese-HFpEF ratmodel to comprehensively phenotype skeletalmuscle
mechanics, blood flow, microvasculature and fibre atrophy. Lean (n = 8) and obese-HFpEF (n = 8)
ZSF1 rats were compared. Skeletal muscles (soleus and diaphragm) were assessed for in vitro contra-
ctility (isometric and isotonic properties) alongside indices of fibre-type cross-sectional area, myosin
isoform, and capillarity, and estimated muscle PO2. In situ extensor digitorum longus (EDL) contra-
ctility and femoral blood flow were assessed. HFpEF soleus demonstrated lower absolute maximal
force by 22%, fibre atrophy by 24%, a fibre-type shift from I to IIa, and a 17% lower capillary-to-fibre
ratio despite increased capillary density (all P < 0.05) with preserved muscle PO2 (P = 0.115) and
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isometric specific force (P > 0.05). Soleus isotonic properties (shortening velocity and power) were
impaired by up to 17 and 22%, respectively (P < 0.05), while the magnitude of the exercise hyper-
aemia was attenuated by 73% (P = 0.012) in line with higher muscle fatigue by 26% (P = 0.079).
Diaphragm alterations (P < 0.05) included Type IIx fibre atrophy despite Type I/IIa fibre hyper-
trophy, with increased indices of capillarity alongside preserved contractile properties during iso-
metric, isotonic, and cyclical contractions. In conclusion, obese-HFpEF rats demonstrated blunted
skeletal muscle blood flow during contractions in parallel to microvascular structural remodelling,
fibre atrophy, and isotonic contractile dysfunction in the locomotor muscles. In contrast, diaphragm
phenotype remained well preserved. This study identifies numerous muscle-specific impairments
that could exacerbate exercise intolerance in obese-HFpEF.
(Received 6 October 2020; accepted after revision 4 December 2020; first published online 21 December 2020)
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Introduction
Increasing prevalence of heart failure with preserved
ejection fraction (HFpEF), in the absence of recognised
pharmaceutical treatments, presents one of the biggest
challenges to modern cardiology (Butler et al. 2014;
Sharma & Kass, 2014; Fukuta et al. 2016). While the
primary pathology of HFpEF is of cardiac origin, there
is a poor correlation between heart dysfunction and the
main symptom of exercise intolerance (Haykowsky &
Kitzman, 2014), and many clinical trials have shown
cardiac-orientated drugs are not associatedwith beneficial
outcomes (Shah et al. 2016). Recent investigations,
therefore, have suggested non-cardiac ‘peripheral’ factors
as major mechanisms limiting functional capacity and
quality of life in patients with HFpEF, with skeletal muscle
abnormalities receiving much attention (Adams et al.
2017; Poole et al. 2018; Zamani et al. 2020). For example,
animal and human studies have shown that HFpEF is
associated with various skeletal muscle impairments that
are closely associated with exercise intolerance and lower
quality of life, including lower skeletal muscle mass and
strength (Bekfani et al. 2016), generalised fibre atrophy
(Bowen et al. 2018), fat infiltration (Haykowsky et al. 2014;
Zamani et al. 2020), reduced global capillary-to-fibre
ratio (Kitzman et al. 2014; Bowen et al. 2018), reduced
mitochondrial function and content (Bowen et al. 2015;
Molina et al. 2016; Bowen et al. 2017b), disrupted
high-energy phosphate metabolism (Bhella et al. 2011b;
Weiss et al. 2017), and impaired O2 extraction (Dhakal
et al. 2015; Houstis et al. 2018; Zamani et al. 2020).
Despite recent progress, our current understanding of
the skeletal muscle pathophysiology in HFpEF at both
the structural and functional level is in its infancy, with
only limited and often conflicting experimental data
available (Poole et al. 2018). For example, it remains
controversial whether leg muscle arterial blood flow (i.e.
perfusive O2 transport) is impaired during exercise in
HFpEF due to a lack of direct measurements (Hundley
et al. 2007; Haykowsky et al. 2013; Lee et al. 2016a;
Weavil et al. 2020), with key studies dependent upon
systemic blood sampling reporting contrasting findings
regarding whether a perfusive or diffusive O2 transport
limitation impairs muscle O2 extraction and thus exercise
intolerance in HFpEF (Dhakal et al. 2015; Houstis et al.
2018; Zamani et al. 2020). As such, there remains a lack
of clarity on whether functional indices related to leg
blood flow and perfusive O2 delivery are constrained
in HFpEF. Likewise, we also have a limited under-
standing of the muscle and microvascular structural
phenotype that occurs with HFpEF. For example, while
studies have shown that a global fibre atrophy is present
alongside a loss of capillaries-per-fibre (Kitzman et al.
2014; Bowen et al. 2015, 2017b, 2018; Schauer et al.
2020), the degree of atrophy and capillary rarefaction
quantified locally across all fibre isoforms which can be
further harnessed to provide novel estimates of muscle
PO2 remains undefined. Furthermore, a knowledge gap
still exists in relation to potential sites of skeletal muscle
dysfunction in HFpEF that include the contribution of
neuromuscular transmission vs. excitation–contraction
failure and/or the impact onmore physiologically relevant
mechanical measures (i.e. shortening velocity and power),
with previous studies performed using only in vitro
isometric contractions under direct muscle stimulation
(Bowen et al. 2015, 2017b, 2018; Schauer et al. 2020).
Beyond this, the majority of experimental work has
been directed towards characterising the locomotor
muscles despite key evidence showing that respiratory
muscle dysfunction is linked to exercise intolerance
in HFpEF, as shown by non-invasive patient measures
(Lavietes et al. 2004; Yamada et al. 2016) and direct
diaphragm contractility measures in experimental models
(Bowen et al. 2015, 2017b). Similar to limb muscle,
however, detailed quantification of diaphragm fibre-type
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morphology, capillarity, PO2, and clinically relevant
functional measurements during cyclical length changes
(i.e. as occurs during breathing) remain largely undefined
in HFpEF and are unlikely to follow a similar response to
the locomotor muscles.
The present study, therefore, aimed to provide a
more comprehensive assessment of the skeletal muscle
phenotype in HFpEF, by applying in vitro, in situ
and in silico approaches to a validated obese cardio-
metabolic rat model, where ex vivo magnetic resonance
imaging was used to characterise the degree of cardiac
remodelling. Specifically, using hindlimb (soleus/EDL)
and respiratory (diaphragm) muscle, we performed
global and local fibre-type specific phenotyping of
cross-sectional area, isoform, and capillarity alongside
estimated muscle PO2. In parallel, we also directly
assessed key functional measures during rest and contra-
ctions, including hindlimb blood flow as well as neural-
and direct-muscle stimulated contractile mechanics. We
reasoned that a better understanding of the skeletalmuscle
phenotype in HFpEF across multiple-system levels would
provide important insights for better understanding the
pathophysiology of exercise intolerance in this disease and
help direct future patient experiments and therapeutic
development in this field.
Methods
Ethical approval
All procedures and experiments were performed in
accordance with the UK Scientific Procedures (Animals)
Act 1986 and local approval was given by the University
of Leeds Animal Welfare and Ethical Review Committee.
All work conforms to the ethical requirements outlined by
The Journal of Physiology (Grundy, 2015).
Animals
Twenty-week-old male obese (n = 8) and lean (n = 8)
diabetic Zucker fatty/spontaneously hypertensive heart
failure F1 hybrid (ZSF1) rats (Charles River Laboratories)
were used in this study. While both lean and obese
ZSF1 rats inherit the hypertension gene, only the obese
ZSF1 rats inherit a mutation in the leptin receptor
gene (LeprfaLeprcp/Crl) that drives weight gain and the
metabolic impairments associated with typical signs of
HFpEF developing as early as 10 weeks of age (Schauer
et al. 2020) and well established after 20 weeks (Leite
et al. 2015; Franssen et al. 2016; van Dijk et al. 2016;
Bowen et al. 2017b). Lean ZSF1 rats served as controls.
All rats were maintained in a 12 h light/dark cycle, with
standard chow diets (RM1 chow, SDS) andwater provided
ad libitum.
Cardiometabolic function
Cardiometabolic impairments were confirmed by
measures of body mass, mean arterial pressure (via
an implanted carotid catheter (PP10)) with a blood
pressure transducer (BP transducer, AD Instruments,
UK) and blood glucose levels (via a commercial blood
glucose meter (FreeStyle Mini Meter), while hearts
were perfused and immersion fixed ex vivo using low
osmolality Karnovsky’s fixative and subsequently imaged
using a diffusion-weighted fast spin echo sequence at a
resolution of 120 μm isotropic for cardiac phenotyping
(Teh et al. 2016). These data were used to calculate mean
thicknesses of the left and right ventricular free walls and
the septum, for tissue located in the middle third of the
distance between the base and apex of the appropriate
ventricular cavity. Myocyte helix angles (quantifying
myocyte inclination with respect to the short axis of
the heart) were extracted from regions in the left and
right ventricular free walls and the septum as previously
described (Benson et al. 2011); myocyte disarray in these
regions was quantified using the R2 of a 5th order poly-
nomial fit to the helix angles plotted as a function of
transmural distance (Benson et al. 2008). All DT-MRI
analyses were carried out using in-house software.
In situ muscle performance and femoral artery blood
flow
In situ measurements of muscle function and blood
flow were made under surgical anaesthesia, which was
induced with isoflurane (4% in 100% oxygen) and
maintained throughout experiments by constant syringe
pump infusion (30–35 mg kg−1 h−1) of Alfaxalone
(Jurox, Crawley, UK) delivered via an implanted jugular
vein catheter. In situ functional assessment of muscle
performance was determined as previously described
(Egginton & Hudlicka, 1999; Tickle et al. 2020). In
brief, extensor digitorum longus (EDL) isometric twitch
force was recorded via a lever arm force transducer
(305B-LR: Aurora Scientific, Aurora, ON, Canada)
following surgical extirpation of the overlying synergist
tibialis anterior muscles. Electrical stimulation of the EDL
(0.3 ms pulse width) was accomplished via electrodes
placed adjacent to the popliteal nerve (Hudlická et al.
1977), with initial electrical pulses (1 Hz) delivered to
determine optimal muscle length and supramaximal
current delivery. Simultaneous measurement of bilateral
blood flow was facilitated by placement of perivascular
flow probes (0.7PSB; Transonic, Ithaca, NY, USA) on
the proximal portion of the femoral artery, adjacent to
the profunda femoris bifurcation (Tickle et al. 2020).
Quantification of resting and end-stimulation blood
flows enabled determination of the functional hyper-
aemia recruited during stimulation. Blood flow data are
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provided (ml min−1) and after normalisation for blood
pressure variation, vascular conductance (ml min−1 mm
Hg−1). All data were recorded via PowerLab and LabChart
software (AD Instruments, UK).
EDL twitch and maximal tetanic force, as well as
fatigue resistance, were also assessed. Fatigue resistance
was quantified by monitoring isometric force throughout
a period of continuous 10 Hz stimulation for 3 min. A
fatigue index was then calculated as: (end-stimulation
twitch tension/peak twitch tension) x 100. An average
of five consecutive twitches was used to quantify end
stimulation and peak EDL tension. Differences in the
magnitude of the absolute tetanic force generated between
groups were taken into account by employing a second
bout of fatigue stimulation, such that absolute forces in
HFpEF were initially similar to those attained in controls
(i.e. matched initial force) (Ferreira et al. 2010). This
protocol is relevant for clinical translation of muscle
fatigue, where daily tasks in patients are often dependent
upon the absolute rather than relative force being
sustained that may involve an increase in firing frequency
of motor neurons to achieve task completion (Weavil et al.
2020). Thus, by adjusting the stimulation frequency in
HFpEF rats to around 25 Hz, tetanic force was increased
and matched to the level recorded in the lean group, with
fatigue allowed to proceed over 3 min. In addition, tetanic
force production was quantified by 200 Hz stimulation
(200 ms duration) after a minimum of 10 min recovery
from fatigue, as determined by restoration of pre-fatigue
resting blood flow.All protocolswere performed in exactly
the same order for each rat, thus minimising any effects of
methodological variation. Force is presented in absolute
units (g) and normalised to wet mass (g mg−1).
In vitro functional assessment
Immediately following killing, the soleus and diaphragm
were excised and prepared in a Krebs–Henseleit solution
(117 NaCl, 4.7 KCl, 1.2 MgSO4, 1.2 KH2PO4, 24.8
NaHCO3, 2.5 CaCl2, 11.1 glucose; in mmol l−1) at 4°C
equilibrated with 95% O2/5% CO2. For the soleus, silk
sutures (4.0) attached to tendons at either end were used
to suspend the muscle vertically in a buffer-filled organ
bath between a hook and a length-controlled lever system
(305C, Aurora Scientific, Aurora, Canada). In vitro field
stimulation using platinum electrodes was provided via a
high power bipolar stimulator (701C, Aurora Scientific)
outputting supramaximal current (700 mA; 1 s train
duration; 0.25 ms pulse width). After optimal contra-
ctile length (L0) was determined, the muscle was thermo-
equilibrated in a Krebs–Henseleit solution for 15 min
at ∼21°C (Bowen et al., 2017a). For the diaphragm, a
bundle of muscle fascicles (∼2–3 mm wide) was removed
from the medial section of the left costal diaphragm
leaving two ribs and a section of the central tendon intact.
The muscle bundle was transferred to a flow-through
muscle chamber and anchored between a base and
ergometer (series 300B-LR, Aurora Scientific Inc.) and
stimulated through parallel platinum electrodes using a
stimulus isolation unit (0.2 ms pulse width; UISO model
236, Hugo Sachs Elektronik). After L0 was determined,
the diaphragm bundle was thermoequilibrated in a
Krebs–Henseleit solution for at least 15 min at 37°C. Each
muscle was circulated with oxygenated (95%O2 /5%CO2)
Krebs–Henseleit solution throughout each experiment.
The soleus underwent two protocols: isometric
force–frequency and isotonic force–velocity. The
force–frequency relationship was determined in response
to pulses at 1, 15, 30, 50, 80, 120 and 150 Hz, with
1 min of recovery between contractions. After a 5 min
period in which muscle length was measured using
digital callipers, the soleus was subjected to a series
of afterloaded-isotonic contractions to determine the
force–velocity relationship, where the muscle was allowed
to shorten against external loads (80 – ∼5% of the
maximal tetanic force; each separated by 1 min for
the soleus or 5 min for the diaphragm) after being
stimulated at 150 Hz for 300 ms. Shortening velocity was
determined 10 ms after the first change in length and on
the linear section of the transient (605A DMA software,
Aurora Scientific). For the diaphragm, maximal isometric
twitch and tetanic (250 ms train at 150 Hz), isotonic
force–velocity (as above), and work loop protocols were
performed. Muscle performance assessed using the work
loop technique included simulating performance in vivo,
by subjecting the muscle to cyclical length changes and
phasic stimulation (Josephson, 1985). A sinusoidal length
change at a range of cycle frequencies (1–15 Hz) and
strain amplitude of 0.065 L0 was imposed on the muscle
and, for each cycle frequency, the timing and duration
of stimulation were optimised to maximise net work.
Isometric tetanic contractions and cyclical contractions at
5 Hz were performed periodically to monitor any decline
in the preparation, assessed by expressing isometric stress
(isotonic contractions) and net work relative to maximal
values. A linear decline in performance was assumed
in correcting data for preparation decline. A period of
5 min was allowed following isotonic and work loop
contractions for recovery. To assess the muscle’s ability to
sustain work, a fatigue test was carried out by subjecting
the muscle to a series of cyclical contractions (cycle
frequency 2 Hz, strain amplitude 0.065 L0, phase −20 ms
relative to peak length, 210 ms stimulation duration).
Custom-written software was used to control muscle
length and stimulation and to acquire length and force
data (CEC Testpoint version 7) via a D/A data acquisition
card (DAS1802AO, Keithley Instruments). Data were
acquired at a sample frequency of 10 kHz (isometric and
isotonic) or 1000 x cycle frequency (work loops).
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At the end of each experiment, the muscle was blotted
on paper tissue and wet mass recorded. Force (N) was
normalised to muscle cross-sectional area (CSA; cm2)
after dividing muscle mass (g) by the product of L0
(cm) and estimated muscle density (1.06 g/cm3) to allow
specific force (i.e. stress) in N/cm2 to be calculated (Close,
1972). Shortening velocity was normalised to optimal
muscle length (in L0/s), while power was calculated as
the product of shortening velocity and force normalised
to muscle mass (in W kg−1). Twitch properties (i.e. peak
force; time-to-peak tension; half relaxation time) as well as
maximal isometric tetanic force (i.e. P0) were calculated. A
hyperbolic-linear relationship was fit to the force–velocity
data to determine the maximum shortening velocity
(Vmax), peak isotonic power (Ẇmax), and the power
ratio (Ẇmax/(P0 ×Vmax); i.e., a measure of the curvature
of the force–velocity relationship (Marsh and Bennet,
1986).
Histological analysis
Mid-portions of the right costal diaphragm and left soleus
muscle were mounted in optimal cutting temperature
embedding medium (Thermo Scientific, Loughborough,
UK), frozen in liquid nitrogen-cooled isopentane
and stored at −80°C. To identify muscle fibre types,
sections (10 μm thick) were fixed for 2 min in 2%
paraformaldehyde, washed in phosphate-buffered saline
(PBS; P4417, Sigma-Aldrich, St Louis, MO) and blocked
for 10 min in 1% bovine serum albumin (A6003,
Sigma-Aldrich, St Louis, MO). Sections were then
incubated for 60 min with monoclonal-myosin heavy
chain antibodies BA-D5 (IgG2B, 1:1000) and SC-71 (IgG1,
1:500) for Type I (oxidative) and Type IIa (fast oxidative,
glycolytic) fibres, respectively (Developmental Studies
Hybridoma Bank, Iowa City, IA, USA). The remaining
unstained fibres were considered to be Type IIb/IIx, as
previously described (Kissane et al. 2018). After washing
in PBS, sections were incubated for 60minwith secondary
antibodies Alexa Fluor 555 (conjugated goat anti-mouse
IgG, 1:1000, A-21422, Thermo Fisher Scientific,Waltham,
MA) and Alexa Fluor 488 (conjugated rabbit anti-mouse
IgG, 1:1000, A11059, Thermo Fisher Scientific, Waltham,
MA). Muscle fibre boundaries were labelled with a rabbit
anti-laminin antibody (1:200; L9393, Sigma-Aldrich, St
Louis, MO), an extracellular matrix glycoprotein within
the basement membrane. Finally, capillaries were stained
with a carbohydrate-binding protein (lectin) specific
to rodent endothelial cells, Griffonia simplicifolia lectin
I (Vector Labs, Peterborough, UK; FL-1101). Slides
were then imaged at magnifications of x10 (soleus)
and x20 (diaphragm) using the Nikon Eclipse E600
(Nikon, Tokyo, Japan) optical microscope attached
to a digital camera (QIMAGING, MicroPublisher 5.0
RTV, Surrey, BC, Canada). Subsequent image analysis
with the stand-alone graphic user interface, DTect,
and a MATLAB-based oxygen transport modeller (The
MathWorks, Cambridge, UnitedKingdom; (Al-Shammari
et al. 2019)) enabled calculation of fibre type-specific
cross-sectional area (FCSA), capillary-to-fibre (C:F) ratio,
capillary density (CD), capillary domain area (CDA),
local capillary-to-fibre ratio (LCFR), local capillary
density (LCD) and estimated tissue oxygen tension (PO2).
Multiple regions of interest of each muscle (three for
the diaphragm and two for the soleus) were randomly
assigned to establish an unbiased counting frame, taking
into account the regional heterogeneity across muscles
(Kissane et al. 2018). In general, each region of inter-
est of the soleus muscle contained ∼155 fibres and the
diaphragm ∼70 fibres.
In silico muscle PO2 modelling
Our model applied mathematical and computational
frameworks to generate theoretical predictions of the
cross-sectional distribution of PO2 in the soleus and
diaphragm using a custom MATLAB ‘oxygen trans-
port modeller’, as previously described (Al-Shammari
et al. 2019). Briefly, using digitised images of muscle
cryosections, individual fibre boundaries were identified,
a phenotype assigned, and capillary locations defined.
A computational framework was then established
allowing a mathematical mesh of equations to be
superimposed on realistic geometry. Tissue PO2
measurements were then derived by incorporating
estimates (applied similarly in each group) of capillary
radius (1.8−2.5× 10−4 cm), muscle oxygen consumption
(15.7 × 10−5 ml O2 ml−1 s−1), myoglobin concentration
(10.2 × 10−3 ml O2 ml−1), O2 solubility (3.89 × 10−5 ml
O2 ml−1 mmHg−1) and diffusivity (1.73 × 10−7 cm2 s−1)
as detailed elsewhere (Al-Shammari et al. 2019), with
direct measurement of these specific parameters beyond
the scope of the present study (Tickle et al. 2020).
As such, any differences between groups in terms of
mitochondrial function (or other assumed variables)
were not accounted for in ourmodel. Relevant biophysical
parameters affecting O2 diffusion from reputable sources
were used in the mathematical model to generate pre-
dictions of the cross-sectional distribution of PO2 in
a muscle biopsy under simulated resting and maximal
oxygen consumption conditions. As with all biological
models, inherent limitations prevent full characterisation
of the wide myriad of interacting variables; however,
relative changes within a given tissue were the key
output and are likely robust. In line with former studies
(Al-Shammari et al. 2019), compensation for differences
in many parameters, e.g. myoglobin saturation, have
relatively small effects on the documented outcomes due
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to the dominant effect of capillary supply and fibre size on
peripheral O2 transport.
Statistical analyses
Following appropriate checks of normality,
between-group differences were assessed by unpaired
two-tailed Student’s t tests. Contractile relationships were
analysed as two-way repeated measures ANOVA followed
by the Bonferroni post hoc test, where appropriate.
Analyses were performed in GraphPad Prism v.8. Data
are presented as means ± SD, and the level of significance
was set at P < 0.05 for all analyses.
Results
Cardiometabolic phenotype
As previously noted (Leite et al. 2015; Franssen et al.
2016; van Dijk et al. 2016; Bowen et al. 2017b; Schauer
et al. 2020), by 20 weeks of age obese-ZSF1 rats have
developed typical metabolic signs associated with HFpEF
including obesity (P < 0.001; Fig. 1A), hyperglycaemia
(P< 0.001; Fig. 1B) and hypertension (P= 0.012; Fig. 1C).
In addition, obese rats developed cardiac remodelling
typically associated with obese-HFpEF that included right
ventricular (RV) hypertrophy (P = 0.034; Fig. 1D),
although left ventricular (LV) and septal wall enlargement
was not observed at this time point (P = 0.719;
Fig. 1E and P = 0.849; Fig. 1F). Further, myocyte
organisation/disarray was not significantly deteriorated
either (RV: P = 0.971; LV: P = 0.13; septum: P = 0.064;
Fig. 1G–H).
Histological and in vitro functional characteristics of
the soleus muscle
As shown in representative muscle sections (Fig. 2A–B),
soleus fromobese-HFpEF rats demonstrated clear atrophy
with a 26% lower wet mass (P < 0.001; Fig. 2C) and a
23% lower CSA of both Type I (P < 0.001) and Type
IIa fibres (P = 0.001; Fig. 2D) when compared with lean
controls. No Type IIx/b fibres were detected in either
group. HFpEF rats also had a lower numerical and areal
composition of Type I fibres (P = 0.002; Fig. 2E and
P = 0.043; Fig. 2F, respectively), whereas these were
higher in Type IIa fibres (P = 0.002 and P = 005,
respectively). In addition, HFpEF rats had a lower C:F
ratio (P = 0.002; Fig. 2G) but a higher CD, indicating
that atrophy proceeded at a greater rate than capillary loss
(P= 0.027; Fig. 2H), while CDAdid not differ significantly
(P= 0.059; Fig. 2I). Analyses of local capillary distribution
revealed that HFpEF rats had lower LCFR in Type I fibres
(P = 0.011), and while a similar trend was found in
Type IIa fibres this did not reach significance (P = 0.154;
Fig. 2J). In contrast, LCD in Type I fibres was higher in
HFpEF rats (P = 0.029), and again while a similar trend
was found in Type IIa fibres this did not reach significance
(P = 0.196; Fig. 2K). To understand whether HFpEF
influenced muscle PO2, we simulated muscle oxygen
tension (PO2) under resting (Fig. 3A–C) and maximal
demand (Fig. 3D–F). No differences between groups were
found after the calculation ofmuscle oxygenation at either
rest (Type I fibres: P = 0.099; Type IIa: P = 0.167; all
fibres: P = 0.102; Fig. 3C) or maximal rate of oxygen
consumption (Type I: P = 0.109; Type IIa: P = 0.177; all
fibres: P = 0.115; Fig. 3F).
The soleus generated lower absolute twitch and
maximal forces in HFpEF than control rats (P < 0.001;
Fig. 4A and P = 0.005; Fig. 4B, respectively), consistent
withmuscle atrophy, although after adjustment formuscle
cross-sectional area there was no difference between
groups in specific forces (P= 0.056, Fig. 4C; andP= 0.557,
Fig. 4D, respectively). Similarly, twitch characteristics of
half relaxation time (P= 0.603; Fig. 4E) and time-to-peak
tension (P = 0.474; Fig. 4F) remained unchanged, as
did the maximal twitch:tetanus ratio between control
and HFpEF (0.16 ± 0.03 vs. 0.14 ± 0.02; P = 0.140).
However, HFpEF rats demonstrated impairments to both
shortening velocity (range 10–17%) and mechanical
power (range 14–22%) when measured across various
percentages of their maximal force (P < 0.05; Fig. 4G–H),
suggesting obese-HFpEF reduces intrinsic soleus contra-
ctile function related to muscle shortening rather than
specific force. Interestingly, however, while Vmax was not
different between groups (1.16± 0.52 vs. 0.88± 0.33 L0/s;
P = 0.307), there was a tendency for the force–velocity
curvature to be 25% greater in HFpEF than controls (i.e. a
lower power ratio: 0.06 ± 0.02 vs. 0.08 ± 0.02; P = 0.086).
In situ muscle function and femoral artery blood flow
EDL muscle wet mass was 26% lower in HFpEF rats
(P < 0.001; Fig. 5A). This corresponded to lower
absolute twitch and maximal forces of 27% and 33%,
respectively (P = 0.016; Fig. 5B and P = 0.030; Fig. 5C,
respectively). When normalised to muscle mass, twitch
and maximal specific forces were not different between
groups (P = 0.968; Fig. 5D and P = 0.675; Fig. 5E,
respectively), while relative fatigability was unaffected
(P = 0.325; Fig. 5F). However, HFpEF rats tended to
be around 26% more fatigable during the force-matched
protocol (P = 0.079; Fig. 5G). While HFpEF rats
had higher levels of resting femoral artery blood flow
(P = 0.039; Fig. 5H), they showed a severely blunted
hyperaemic response of 73% to repeated contractions
(P = 0.012; Fig. 5I). Similarly, impairments in the hyper-
aemia calculated using vascular conductance was found
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Figure 1. Cardiometabolic characteristics
At 20 weeks of age, HFpEF rats developed obesity (426.25 ± 15.41 vs. 529.88 ± 29.56 g P < 0.001) (A),
hyperglycaemia (8.38 ± 1.69 vs. 19.10 ± 3.83 mmol l−1; P < 0.001) (B) and hypertension (154.26 ± 11.28
vs. 172.03 ± 12.26 mmHg; P = 0.012) (C). Compared with lean controls, obese-HFpEF rats also showed increased
right ventricular (RV) wall thickness (0.74 ± 0.04 vs. 0.82 ± 0.04 mm; P = 0.034) (D); however, left ventricular (LV)
wall and the septum thickness were not different between groups (2.68 ± 0.51 vs. 2.55 ± 0.46 mm; P = 0.719
and 2.22 ± 0.38 vs. 2.16 ± 0.49 mm; P = 0.849, respectively) (E–F). Left and middle panels: long axis cuts (left)
and short axis slices (middle) of representative lean (G) and obese (H) hearts, with myocyte helix (inclination) angle
colour coded on the cut surfaces. Right panel: the helix angle in the RV free wall plotted as a function of fractional
transmural distance (0.0, endocardium; 1.0, epicardium) for representative lean (G) and obese (H) hearts. The red
continuous line is a 5th order polynomial fit to the data. Myocyte disarray is quantified by the R2 of this fit.
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Figure 2. Histological features of the soleus muscle
Representative soleus sections from control (A) and obese-HFpEF (B). Obese-HFpEF showed atrophy in the soleus
muscle, with reduced wet muscle mass (206.54 ± 15.48 vs. 152.50 ± 12.55 mg; P < 0.001) (C) and reduced
cross-sectional area (CSA) in both Type I (3921.88 ± 316.51 vs. 3009.75 ± 298.03 μm2; P < 0.001) and Type IIa
fibres (3351.43 ± 422.09 vs. 2575.69 ± 296.86 μm2; P = 0.001) (D). HFpEF rats also had a lower numerical and
areal composition of Type I fibres (95.49 ± 2.45 vs. 87.84 ± 5.32%, P= 0.002 and 96.06 ± 2.17 vs. 84.06 ± 15.14
%, P = 0.043, respectively), whereas these were higher in Type IIa fibres (4.51 ± 2.45 vs. 12.16 ± 5.32 %,
P = 0.002 and 3.94 ± 2.17 vs. 10.74 ± 5.31 %, P = 0.005, respectively) (E-F). Moreover, compared with lean
controls, obese rats had reduced capillary-to-fibre (C:F) ratio (2.37 ± 0.26 vs. 1.96 ± 0.13; P= 0.002) (G), whereas
capillary density (CD), was increased (438.23 ± 57.66 vs. 505.5 ± 51.53 mm−2; P = 0.027) (H) with no change
in capillary domain area (CDA) (2363.28 ± 410.48 vs. 2024.48 ± 223.24 μm2; P = 0.059) (I). Finally, local
analyses of capillary distribution showed that HFpEF rats had lower local capillary-to-fibre ratio (LCFR) in Type I
fibres (1.78 ± 0.22 vs. 1.53 ± 0.10; P = 0.011), although this was unchanged in Type IIa fibres (1.43 ± 0.27 vs.
1.24 ± 0.21; P = 0.154) (J). In contrast, local capillary density (LCD) in Type I fibres was increased in HFpEF rats
(440.41 ± 59.71 vs. 510.15 ± 54.9 mm−2; P = 0.029), with no changes in Type IIa fibres (423.20 ± 88.64 vs.
474.73 ± 56.17 mm−2; P = 0.196) (K).
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in HFpEF (P = 0.004; Fig. 5J). Overall, this suggests that
while obese-HFpEF does not induce muscle dysfunction
related to neuromuscular transmission failure, a severe
decrement to increase leg blood flow in response to
contractions is apparent.
Histological and functional characteristics of the
diaphragm
Representative diaphragm sections from control and
HFpEF rats are presented in Fig. 6A–B. Average FCSAwas
similar between groups (P = 0.609; Fig. 6C). However,
Figure 3. Modelling of soleus muscle oxygen tension
Simulation of muscle PO2 at rest (A–B) and maximal rate of oxygen consumption (D–E) in representative images.
There were no significant differences in simulations of muscle PO2 at rest (Type I fibres: 27.26 ± 0.33 vs.
27.54 ± 0.30 mmHg, P= 0.099; Type IIa: 27.12 ± 0.39 vs. 27.37 ± 0.31 mmHg, P= 0.16; all fibres: 27.25 ± 0.33
vs. 27.52 ± 0.29 mmHg, P = 0.102) (C) or at maximal rate of oxygen consumption (Type I: 18.97 ± 1.38 vs.
20.11± 1.27 mmHg, P= 0.109; Type IIa: 18.00± 1.64 vs. 19.07± 1.36 mmHg, P= 0.177; all fibres: 18.92± 1.36
vs. 20.02 ± 1.24 mmHg, P = 0.115) (F). Areas of muscle hypoxia (PO2 < 0.5 mmHg) are highlighted in blue.
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compared with lean controls HFpEF increased FCSA in
both Type I and Type IIa fibres by 46% (P < 0.001) and
26% (P = 0.005), respectively (Fig. 6C), but reduced Type
IIb/IIx FCSA by 22% (P = 0.004). Additionally, HFpEF
rats had a higher numerical percentage of Type I fibres
(P = 0.003; Fig. 6D) and a higher area percentage of Type
I fibres (P < 0.001; Fig. 6E).
Global and local alterations were also observed in
capillary distribution, with C:F ratio and CD increased
in HFpEF rats (P = 0.015; Fig. 6F and P = 0.049;
Fig. 6G, respectively) but CDA did not differ significantly
(P = 0.362; Fig. 6H). HFpEF rats had increased LCFR
in Type I (P < 0.001) and Type IIa fibres (P < 0.001),
whereas this was reduced in Type IIb/IIx fibres (P= 0.040;
Fig. 6I). In contrast, LCD was higher in HFpEF for Type
IIb/IIx fibres (P = 0.042), with no changes in Type I
(P= 0.152) andType IIa fibres (P= 0.128; Fig. 6J).Wenext
estimated diaphragm PO2 levels (Fig. 7A–B) and found
Figure 4. In vitro skeletal muscle function
The soleus of HFpEF rats showed lower absolute twitch force (28.79 ± 3.23 vs. 20.01 ± 3.10 g; P < 0.001) (A)
and absolute maximal tetanic force (178.95 ± 26.18 vs. 139.37 ± 17.05 g; P = 0.005) (B), although mass-specific
twitch and maximal forces were similar between groups (3.36 ± 0.50 vs. 2.86 ± 0.39 N/cm2; P = 0.056 and
20.72 ± 2.28 vs. 19.98 ± 2.29 N/cm2; P = 0.557, respectively) (C–D). Similarly, time-to-peak tension and half
relaxation time remained unchanged (23.10 ± 2.25 vs. 22.18 ± 2.75 ms; P = 0.474 and 41.68 ± 16.33 vs.
46.08 ± 16.70 ms; P = 0.603, respectively) (E–F). However, HFpEF rats showed impairments in shortening velocity
and muscle power when measured across different percentages of their maximal force (30, 40 and 50%) (P< 0.05)
(G–H).
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HFpEF elevated resting muscle oxygen tension (Type I
fibres: P = 0.043; Type IIa: P = 0.019; Type IIb/IIx:
P = 0.006; all fibres: P = 0.009; Fig. 7C) and at maximal
metabolic rates (Type I: P = 0.045; Type IIa: P = 0.018;
Type IIb/IIx: P = 0.004; all fibres: P = 0.006; Fig. 7F),
indicating improvedmuscle oxygenation in obese-HFpEF.
Isometric twitch and maximal tetanic stress of the
diaphragm were similar between groups (P = 0.254;
Fig. 8A and P = 0.225; Fig. 8B, respectively). However,
analysis of twitch kinetics demonstrated that HFpEF
rats had a slower time-to-peak tension (P = 0.006;
Fig. 8C) while half relaxation time remained unchanged
(P = 0.170; Fig. 8D) as did the maximal twitch:tetanus
ratio between control and HFpEF (0.31 ± 0.06 vs.
0.32 ± 0.05; P = 0.630). Similarly, there were no
differences in isotonic properties as assessed by maximal
shortening velocity or maximal isotonic power between
groups (P = 0.756; Fig. 8E and P = 0.670; Fig. 8F),
with the power ratio also not different between groups
(0.11± 0.01 vs. 0.11± 0.01;P= 0.253).During the cyclical
contractions, there were no differences in the net power
recorded at any given frequency and no difference in the
cycle frequency that yielded maximum net power (i.e.
5 Hz for both groups) (all P > 0.05; Fig. 8G). However,
during repeated cyclical contractions the ability of the
diaphragm to sustain work and power relative to the
unfatigued state was reduced in HFpEF compared with
controls (P = 0.001) and this occurred after relatively few
cycles of work (cycles 6–12; P < 0.05; Fig. 8H).
Discussion
This study has identified novel skeletal muscle
impairments in obese-HFpEF that likely predispose
towards the pathophysiology of exercise intolerance. The
main findings from this study are:
(1) Limb muscle weakness was closely associated with
fibre atrophy in HFpEF, but isometric contractile
properties were not impaired under neural- or
direct-muscle assessments, indicating preserved iso-
metric neuromuscular function.
(2) In contrast, limb isotonic muscle properties including
shortening velocity and mechanical power were
impaired in HFpEF.
(3) An abnormal leg blood flow response to contractions
alongside fibre type-specific structural capillary loss
Figure 5. In situ EDL contractile function and femoral artery blood flow
Absolute twitch and maximal tetanic forces of the EDL muscle were lower in HFpEF rats than in controls
(57.24 ± 13.82 vs. 41.62 ± 11.31 g, P = 0.016 and 224.64 ± 66.36 vs. 151.38 ± 45.45 g, P = 0.030,
respectively) (B–C). However, when normalised to muscle mass, which was reduced in HFpEF rats (262.88 ± 22.47
vs. 194.73 ± 15.35 mg; P < 0.001) (A), these were not significantly affected (0.22 ± 0.05 vs. 0.22 ± 0.07 g mg−1
EDL, P < 0.968 and 0.82 ± 0.23 vs. 0.77 ± 0.21 g mg−1 EDL, P = 0.675, respectively) (D–E). The fatigue index
was similar between groups (0.46 ± 0.12 vs. 0.51 ± 0.09 %; P = 0.325) (F). However, HFpEF rats tended to be
more fatigable during the force-matched protocol (45.96 ± 11.96 vs. 34.35 ± 12.08; P = 0.079) (G). Resting
femoral artery blood flow was augmented in HFpEF rats (1.71 ± 0.33 vs. 2.66 ± 0.90 ml min−1; P = 0.039)
(H). In contrast, HFpEF rats showed an impaired increase in muscle-specific EDL blood flow during stimulation
(2.59 ± 1.30 vs. 0.69 ± 0.37 ml min−1 g−1; P = 0.012) (I). Moreover, a reduction in the functional hyperaemic
scope was also found in HFpEF (3.22 ± 1.12 vs. 1.27 ± 0.15; P = 0.004) (J).
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Figure 6. Histological features of the diaphragm
Representative diaphragm sections from control (A) and obese-HFpEF (B). Compared with lean controls, HFpEF
rats had increased cross-sectional area (CSA) in Type I (1130.67 ± 30.45 vs. 1647.83 ± 286.52 μm2; P < 0.001)
and Type IIa fibres (1352.19 ± 133.46 vs. 1709.33 ± 273.24 μm2; P = 0.005), whereas CSA of Type IIb/IIx
fibres was reduced (3109.90 ± 222.49 vs. 2418.50 ± 514.36 μm2; P = 0.004) (C). HFpEF rats also had a
higher numerical percentage of Type I fibres (32.93 ± 3.46 vs. 38.38 ± 2.64 %; P = 0.003), although this
remained unchanged in Type IIa (34.41 ± 4.39 vs. 30.65 ± 6.67 %; P = 0.203) and IIb/IIx fibres (32.63 ± 3.43
vs. 31.00 ± 6.63 %; P = 0.545) (D). Additionally, HFpEF rats showed a higher area percentage of Type I fibres
(20.26 ± 2.37 vs. 33.12 ± 3.85 %; P < 0.001), whereas this was unchanged in Type IIa fibres (25.38 ± 3.50 vs.
27.66 ± 7.47 %; P = 0.449) and reduced in Type IIb/IIx fibres (54.36 ± 3.83 vs. 39.23 ± 10.33; P = 0.002)
(E). HFpEF rats also showed general and local alterations in capillary distribution. General changes included
increased capillary-to-fibre (C:F) ratio (1.96 ± 0.12 vs. 2.26 ± 0.28; P = 0.015) (F) and capillary density (CD)
(733.42 ± 51.94 vs. 822.30 ± 104.43 mm2; P = 0.049) (G), although capillary domain area (CDA) remained
unchanged (1600.57 ± 371.08 vs. 1420.58 ± 392.25 μm2; P= 0.362) (H). Local changes included increased LCFR
in Type I (0.92 ± 0.08 vs. 1.39 ± 0.14; P < 0.001) and Type IIa fibres (1.05 ± 0.04 vs. 1.51 ± 0.16; P < 0.001) and
reduced local capillary-to-fibre ratio (LCFR) in glycolytic/Type IIb/IIx fibres (2.13 ± 0.21 vs. 1.78 ± 0.37; P = 0.040)
(I). In contrast, however, HFpEF rats had increased local capillary density (LCD) in Type IIb/IIx fibres (615.85 ± 45.69
vs. 700.85 ± 97.37 mm2; P = 0.042), with no changes in Type I (765.26 ± 60.76 vs. 843.27 ± 132.38 mm2;
P = 0.152) and Type IIa fibres (763.78 ± 68.71 vs. 842.75 ± 119.64 mm2; P = 0.128) (J).
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was found in HFpEF, indicating perfusive O2 trans-
port limitations.
(4) Significant remodelling of the diaphragm occurred
in HFpEF including divergent fibre-type hyper-
trophy/atrophy, higher capillarity/PO2, and a Type
II-to-I fibre-type shift, with preserved muscle
mechanics.
Impact of HFpEF on limb muscle function
A reduction in skeletal muscle mass in patients with
HFpEF is strongly associated with reduced muscle
strength and poor quality of life (Bekfani et al. 2016).
Muscle weakness is generally underpinned by either a
reduction in muscle mass (i.e. atrophy) and/or intrinsic
Figure 7. Modelling of diaphragm oxygen tension
Simulation of muscle PO2 at rest (A–B) and maximal rate of oxygen consumption (D–E) in representative images.
Compared with lean controls, HFpEF rats showed higher muscle oxygen tension at rest (Type I fibres: 28.09 ± 0.39
vs. 28.45 ± 0.24 mmHg, P = 0.043; Type IIa: 27.80 ± 0.52 vs. 28.35 ± 0.27 mmHg, P = 0.019; Type IIb/IIx:
27.26 ± 0.70 vs. 28.13 ± 0.29 mmHg, P = 0.006; all fibres: 27.55 ± 0.61 vs. 28.28 ± 0.27, P = 0.009) (C)
or at maximal rate of oxygen consumption (Type I: 22.29 ± 1.57 vs. 23.76 ± 1.06 mmHg, P = 0.045; Type IIa:
20.52 ± 2.27 vs. 22.95 ± 1.22 mmHg, P = 0.018; Type IIb/IIx: 17.33 ± 3.24 vs. 21.58 ± 1.39 mmHg, P = 0.004;
all fibres: 19.07 ± 2.78 vs. 22.58 ± 1.26 mmHg, P = 0.006) (F).
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contractile dysfunction. In this study, we used in vitro
(i.e. direct muscle) and in situ (i.e. peripheral nerve)
stimulation approaches to assess isometric contra-
ctile properties in limb muscle. This allowed various
sites in the muscle contractile process to be evaluated
for dysfunction in HFpEF, including neuromuscular
transmission and excitation–contraction coupling.
Consistent with previous data where absolute maximal
soleus force was reduced by ∼20% in HFpEF rats vs.
controls (Bowen et al. 2018; Schauer et al. 2020), we
observed that absolute twitch and maximal forces
in both the soleus and EDL were lower in HFpEF
rats. However, limb muscle weakness was closely
associated with fibre atrophy as, after normalising
for muscle mass, specific forces were not different
between groups independent of whether the neural
and blood supply remained intact. This is important,
as it indicates that neuromuscular transmission
and excitation–contraction coupling is likely preserved
under isometric contractions in obese-HFpEF.
Figure 8. Functional properties of the diaphragm
Isometric twitch and tetanic stress of the diaphragm were not different between groups (7.24 ± 2.87 vs.
8.83 ± 2.47 N/cm2, P = 0.254 and 23.09 ± 6.56 vs. 27.46 ± 7.22 N/cm2, P = 0.225, respectively) (A–B). In
contrast, HFpEF rats showed slowed time-to-peak tension (16.48 ± 1.29 vs. 18.50 ± 1.21 ms; P = 0.006) (C),
although half relaxation time was not significantly affected (19.30 ± 3.68 vs. 21.45 ± 2.02 ms; P = 0.170) (D).
There were no differences in maximal shortening velocity (Vmax) (9.10 ± 1.11 vs. 8.32 ± 1.46 Lo/s; P= 0.278) (E) or
peak isotonic power (212.56± 59.28 vs. 226.11 ± 69.36 W kg−1; P = 0.701) (F) between groups. During cyclical
contractions, while the net power-cycle frequency relationship remained unaltered between groups (P > 0.05;
typical work loops are shown at each cycle frequency for each group) (G), relative fatigue was greater in HFpEF
(P < 0.001) under cycles 6–12 (H).
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However, most daily activities require the muscle to
shorten against different loads to generate mechanical
power and thus perform work. Therefore, assessment of
muscle isotonic properties such as shortening velocity and
power, which remained undefined in HFpEF, provides a
more relevant assessment in relation to daily patient
activities. Here, we observed that HFpEF rats had
impairments to both shortening velocity and mechanical
power in the soleus. This functional loss in HFpEF cannot
be explained by a simple shift towards more Type I
fibres (i.e. typically associated with slower shortening
velocities where myosin heavy chain isoform is a key
determinant (Bottinelli et al. 1991)), as we observed a
higher proportion of Type IIa fibres in HFpEF (i.e., a Type
I-to-II fibre-type shift). As such, while this rules out a
Type I fibre-type shift as a potential mechanism under-
lying the slower shortening velocities observed in HFpEF,
shortening velocity is also thought to be limited by the rate
of ADP dissociation from actomyosin (Nyitrai et al. 2006).
Thus, our data suggest obese-HFpEF rats develop slowed
rates of cross-bridge detachment through impaired
ADP release, potentially due to post-translational
modifications of myosin related to oxidative stress or
glycation, as previously reported in HFrEF (Coirault
et al. 2007) and ageing (Ramamurthy et al. 1999). In
further support, slowed cross-bridge kinetics have pre-
viously been reported in Type I and IIa fibres of vastus
lateralis biopsies from patients with HFrEF (Miller et al.
2010), although other mechanisms such as impaired
sarcoplasmic reticulum calcium pumping cannot be ruled
out. Interestingly, we also found a tendency in the soleus
for the curvature of the force–velocity relationship to be
greater in HFpEF than the controls (i.e. where curvature
is the inverse of the a/P0 ratio in the Hill equation), which
is in line with previous studies highlighting significant
power loss during fatiguing exercise when the curvature
is greater (or a/P0 lower) (Jones, 2010). As such, a greater
curvature of the force–velocity relationship may be
another potential mechanism contributing to the loss
of power observed in HFpEF. Overall, therefore, the
significant loss of absolute limb force associated with
muscle atrophy in obese-HFpEF alongside intrinsic
impairments related to lower shortening velocity and
increased curvature would be predicted to severely reduce
mechanical power and thus predispose towards exercise
intolerance.
Impact of HFpEF on limb skeletal muscle morphology
Despite skeletal muscle morphological alterations being
well investigated in HFrEF (Kennel et al. 2015), little
information is available on HFpEF from either animal or
patient studies. Previous data from patients with HFpEF
indicated the vastus lateralis Type I to Type II fibre-type
shift and a lower global C:F ratio, which is associated with
reduced V˙O2peak (Kitzman et al. 2014). Animal models
(hypertensive or cardiometabolic) have shown in the
soleus/EDL a significant fibre atrophy and a lower global
C:F ratio (Bowen et al. 2015, 2017b, 2018; Schauer et al.
2020). Consistent with this, in the present study we found
that soleus muscle from HFpEF rats exhibited a fibre
atrophy of 24% and a Type IIa fibre-type shift alongside
a lower global C:F ratio of 17%. In contrast, however,
we also provide new evidence that CD in the soleus was
higher in HFpEF rats by 15% vs. controls, and by using
novel local measures of capillarity (i.e. LCRF, LCD), we
identified thatwhile a similar trendwas found in both fibre
types, only Type I reached statistical significance. These
additional local indices allowed us to further conclude
that the lower C:F ratio observed in HFpEF was the result
of a greater contribution from Type I fibres (i.e. LCRF),
suggesting that slow- rather than fast-twitch fibres tended
to be more susceptible to microvascular alterations in this
disease. However, the capillary supply per cross-sectional
area of Type I fibres (LCD) was in fact higher in HFpEF
muscle. These global and local measures of capillarity
where the C:F ratio was lower but CD higher in HFpEF
are likely explained by the observed fibre atrophy, as CD is
highly dependent upon fibre size (Egginton, 2011). This
indicates that the degree of fibre atrophy exceeded the
rate of capillary loss in HFpEF, thus increasing the CD,
which has been suggested as an adaptive process to reduce
diffusion distances across muscle fibres (Al-Shammari
et al. 2019), helping to discriminate structural from
functional consequences of microvascular remodelling.
A reduced distance for oxygen diffusion could be the
result of an adaptation to changes in leg blood flow, as
we observed. In HFpEF, this may also be a compensatory
mechanism to preserve O2 flux from capillary to myocyte
and thus maintain a better PO2 status across the muscle,
not only in the face of capillary loss but also in response
to the reported deficits in mitochondrial O2 utilisation
(Bowen et al. 2015, 2017b; Molina et al. 2016).
In this regard, data collected from patients with HFpEF
have identified clear impairments in the ability to widen
arterial–venous O2 content (AVO2) and augment peri-
pheral oxygen extraction during exercise compared with
HFrEF or controls (Haykowsky et al. 2011; Bhella et al.
2011a; Dhakal et al. 2015; Houstis et al. 2018; Zamani
et al. 2020). It remains unclear whether the capillary loss
we observed contributes to abnormal skeletal muscle O2
extraction at peak exercise in HFpEF, with a peripheral
O2 diffusive limitation postulated as a major mechanism
underpinning exercise intolerance in HFpEF (Dhakal
et al. 2015; Houstis et al. 2018). To expand current
knowledge (Dhakal et al. 2015;Houstis et al. 2018; Zamani
et al. 2020), we therefore used in silico modelling to
provide the first fibre-type specific estimates of micro-
vascular contribution to muscle oxygenation in HFpEF.
We found muscle PO2 was similar between HFpEF and
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controls during simulated rest and at maximal exercise,
which indicates adequate oxygenation is maintained in
HFpEF with no evidence for enhanced tissue hypoxia.
A recent patient study using forearm exercise found
estimated peripheral O2 diffusion was not different
between HFpEF and controls (Zamani et al. 2020),
but this contrasts with previous cycling studies where
O2 diffusion was significantly lower based on systemic
haemodynamic, blood gas and pulmonary gas exchange
measurements (Dhakal et al. 2015; Houstis et al. 2018).
It should be noted that these patient studies did not
measure leg/muscle AVO2, fibre size, capillarity, or
microvascular distribution, which can all influence peri-
pheral O2 diffusion. While the current data do not allow
us to directly confirm whether O2 diffusion was impaired
in obese-HFpEF, our data suggest that fibre morphology
and capillary distribution are unlikely to contribute to O2
diffusive limitations.
Interestingly, and in contrast to HFrEF or controls,
patients with HFpEF are unable to lower venous PO2
during exercise and therefore demonstrate a blunted peri-
pheral O2 extraction response (Dhakal et al. 2015; Houstis
et al. 2018; Poole et al. 2018; Zamani et al. 2020). The
extent of this impaired muscle O2 extraction in HFpEF
is likely explained, at least in part, by the significant
mitochondrial abnormalities reported in patients with
HFpEF (Molina et al. 2016). In our study, estimated
muscle PO2 in HFpEF was not lower than controls at
simulated maximal exercise, and while not discounting
the potential for a muscle O2 diffusion limitation (Poole
et al. 2018), this is consistent with maintenance of a
high muscle oxygenation across the muscle in HFpEF
to support more optimally functioning mitochondria
(Al-Shammari et al. 2019). Clearly, more studies are
warranted to clarify the role of limitations to muscle
O2 diffusion in HFpEF. However, our present data of a
reduced leg blood flow (see below) implicate a perfusive
O2 delivery limitation as one key mechanism that could
potentially blunt O2 extraction in obese-HFpEF.
Impaired muscle blood flow response in HFpEF
Up until now, direct measures of leg (muscle) arterial
blood flow had not been assessed in HFpEF, limiting
mechanistic understanding. In the present study, using
perivascular flow probes (the gold standard for measuring
volumetric blood flow in animal studies), we directly
demonstrated that the functional hyperaemic response
to contractions was blunted in HFpEF rats. These data
support the concept that the peripheral response to
exercise is impaired in HFpEF (Houstis et al. 2018),
and are consistent with non-invasive measurements
in patients with HFpEF during knee-extensor exercise
where impaired leg blood flow and vascular conductance
occurred independently of limitations to heart rate,
stroke volume and cardiac output (Lee et al. 2016b;
Weavil et al. 2020) but contrast with recent isometric
forearm data which did not find any change (Zamani
et al. 2020). However, some (Maréchaux et al. 2016;
Lee et al. 2016b; Kishimoto et al. 2017; Weavil et al.
2020) but not others (Hundley et al. 2007; Haykowsky
et al. 2013; Lee et al. 2016a; Zamani et al. 2020)
report an abnormal blood flood response to exercise in
HFpEF patients when compared with controls, which
is probably related to differences in the muscle studied,
non-invasive and different measurement techniques,
and patient heterogeneity. Overall, our data support
the potential for perfusive, feed-artery O2 transport
limitations in HFpEF, which likely contributes to exercise
intolerance in this disease (Poole et al. 2018; Weavil et al.
2020).
Although the mechanisms underlying abnormal limb
blood flow response to exercise in HFpEF remain unclear,
endothelial function is impaired (Schmederer et al. 2018)
and postulated as a central mechanism underlying disease
progression (Paulus & Tschöpe, 2013; Gevaert et al. 2017;
Schmederer et al. 2018). Beyond this, upstream central
impairments related to cardiac output likely play a major
role (Wolsk et al. 2019). While the functional significance
of an impairment to limb blood flow during exercise
in HFpEF is not known, it may exacerbate the degree
of muscle fatigue experienced and limit daily activities
performed by patients where the ability to repeatedly
sustain absolute forces rather than relative forces becomes
crucial, as recently demonstrated in patients with HFpEF
(Weavil et al. 2020). This is supported by our employed
matched-initial force fatigue protocol, where HFpEF
rats showed a trend to be 26% more fatigable than
controls. These data provide important clinical relevance,
as patients with muscle weakness such as HFpEF are often
required to increase motor firing frequencies to perform
certain daily activities that induce early fatigue (Ferreira
et al. 2010; Weavil et al. 2020), although it is important to
note this may not necessarily reflect direct differences in
relation to muscle fatigue properties. Our data therefore
indicate that skeletal muscle arterial blood delivery is
potentially constrained during exercise inHFpEF.As such,
at least in the context of this animal model and in support
of recent patient findings (Weavil et al. 2020), a perfusive
O2 delivery limitation could play a key role limiting O2
extraction and thus exacerbating exercise intolerance in
obese-HFpEF (Poole et al. 2018; Zamani et al. 2020).
Interestingly, a lower leg blood flow during contractions
coupled with a higher muscle CD in obese-HFpEF could
result in an increased red blood cell transit time tomediate
a greater O2 extraction. However, thismay not transpire in
HFpEF due to the significantmitochondrial abnormalities
developed in patients (Molina et al. 2016), thus preventing
any significant widening of the AVO2.
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Impact of HFpEF on diaphragm remodelling and
muscle mechanics
Inspiratory (i.e. diaphragm) muscle weakness is evident
and closely associated with symptoms of dyspnoea and
poor prognosis in patients with HFpEF (Lavietes et al.
2004; Hamazaki et al. 2020). Multiple alterations to the
diaphragm have been reported in HFpEF, including in
vitro muscle weakness and fatigue alongside a Type
II-to-I fibre-type shift, fibre atrophy, and impaired in
situ mitochondrial respiration in a hypertensive rat
model (Bowen et al. 2015). In contrast, we show
remodelling of the HFpEF diaphragm that is reminiscent
of exercise-training including fibre hypertrophy, increased
mitochondrial content, and preserved fatigue resistance,
although evidence for mitochondrial uncoupling and a
mild isometric contractile dysfunction have been noted
(Bowen et al. 2017b). The disparity in findings between
models is likely explained by the co-morbidity of obesity
and its associated chronic respiratory loading, which
can act as a training stimulus to increase fibre size,
mitochondrial function/content, and fatigue resistance
(Farkas et al. 1994; Powers et al. 1996). Whether similar
findings are observed between obese vs. lean patients with
HFpEF remains unknown.
Given that approximately 80% of HFpEF patients are
obese (Shah et al. 2016) and a recent distinct obese-HFpEF
phenotype has been established (Obokata et al. 2017),
the present study contributes novel and highly relevant
data in relation to diaphragm plasticity. Until now,
only limited data have been available with respect to
fibre-type structure, isoform, and microvasculature of
the diaphragm in HFpEF (Bowen et al. 2015, 2017b). In
the present study, we identified three major fibre types
(Types I, IIa and IIb/IIx) to provide new evidence of
a divergent hypertrophy/atrophy fibre remodelling in
obese-HFpEF alongside increased indices of global and
local capillarity (i.e. C:F ratio and CD), and estimated
levels of fibre oxygenation at rest and maximal exercise.
Specifically, compared with controls, obese-HFpEF
rats had increased Type I/IIa FCSA, and reduced Type
IIb/IIx FCSA, indicating compensatory adaptations
in slow-twitch fibres. This observation corresponds
to the morphometric alterations following unilateral
denervation of rat diaphragm muscle, where hypertrophy
in Type I fibres but atrophy in Type IIb/IIx fibres occurred
(Aravamudan et al. 2006). In support, albeit in the limb
gastrocnemius, denervation has been demonstrated
to induce fibre atrophy at a relatively higher rate than
capillary rarefaction to mediate a higher CD (Paudyal
et al. 2018), which is in line with our findings from the
diaphragm in HFpEF. Nevertheless, it remains unclear
whether obese-HFpEF induces partial diaphragm muscle
denervation in fast-twitch Type IIb/x as reported in other
conditions such as ageing (Elliott et al. 2016).
Overall the obese-HFpEF diaphragm demonstrates
improved indices of oxygen transport (increased
capillarity and PO2 distribution) that likely supports
the observed shift towards an oxidative phenotype (i.e.
higher proportion of Type I fibres, mitochondrial content,
and antioxidative enzyme capacity (Bowen et al. 2015,
2017b). This suggests that any functional diaphragm
impairments developed in obese-HFpEF were likely
offset by morphological adaptations. To decipher this
potential trade-off, we performed in vitro isometric,
isotonic and cyclical contractions on the diaphragm
in one of the most detailed functional assessments
in HFpEF to date. Our data indicate that impaired
muscle mechanics and intrinsic diaphragm dysfunction
generally do not develop early in the time course of
obese-HFpEF (∼20 weeks), with only a mild increase
found compared with controls in terms of fatigability.
Again, these data conflict with previous experimental
data where a significant reduction in diaphragm force
during repeated isometric contractions was measured in
rats with more advanced hypertensive-induced HFpEF
(Bowen et al. 2015). In the present study we also simulated
in vivo respiratory muscle mechanics, by applying cyclical
length changes and phasic stimulation to the muscle to
generate cycles of work, using the in vitro work loop
technique (Josephson, 1985). Similar to our isolated
isometric and isotonic measures, net power output
during unfatigued cyclical contractions in obese-HFpEF
was unaffected in the diaphragm, but we did observe a
mild increase in fatigue during repeated cyclical contra-
ctions. Collectively, these data suggest that respiratory
muscle dysfunction is unlikely to be a key player in the
pathogenesis of exercise intolerance in obese-HFpEF, at
least during early disease progression.
Study limitations
We did not use echocardiography or invasive
haemodynamics to quantify the extent of LV diastolic
function and ejection fraction. However, this rat model
has been validated and consistently develops key features
of HFpEF as early as 10–15 weeks of age (Schauer et al.
2020), including impaired diastolic function, preserved
ejection fraction, myocardial remodelling, and exercise
intolerance (Hamdani et al. 2013; Leite et al. 2015;
Franssen et al. 2016; van Dijk et al. 2016; Bowen et al.
2017b). Instead, we used MRI to confirm the presence of
cardiac remodelling which occurred in the RV and this is
known to be closely associated with HFpEF development
in obese patients (Obokata et al. 2017) and one of the
strongest predictors of poor prognosis (Burke et al. 2014).
We also compared groups at a relatively early time point
in the progression of HFpEF, which may limit trans-
lation of our findings to more advanced stages of the
© 2020 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society.
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disease. In addition, our experiments were performed
in male rats only such that it remains unclear whether
similar findings would be observed in females, although
a recent study confirmed that a similar time course in
disease progression is observed in females (Schauer et al.
2020). Further, while differences in physical activity levels
between groups were not measured and cannot be ruled
out as having an influence on our experimental measures,
it is well established that disuse alone fails to account for
the skeletal muscle impairments developed during heart
failure (Simonini et al. 1996; Miller et al. 2009). While we
saw a trend for fatigue to be higher in HFpEF under our
matched-initial force protocol, this was only performed
in n = 4 and thus may have been underpowered to
detect statistical, rather than biologically meaningful,
differences. Furthermore, as with all biological models,
inherent limitations should be considered and our
estimated muscle PO2 values from this study were based
on a number of assumptions (as detailed in Methods)
and may not be directly comparable to humans due to
allometric scaling and/or fibre-type differences.
Conclusions
Obese-HFpEF rats have a blunted hindlimb blood
flow response to contractions alongside microvascular
structural remodelling, fibre atrophy, and isotonic contra-
ctile dysfunction, which may be important factors under-
lying exercise intolerance in this disease. In contrast,
diaphragm phenotype was largely preserved, indicating
a more prominent role for limb rather than respiratory
muscle abnormalities in obese-HFpEF.
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